Merck, like many other companies, has experienced a number of manufacturing challenges that prevented us from being able to meet global demand for a number of our vaccines. As a result, some of our vaccines have been on back order and others have been unavailable for order for some time.
We are working to address those challenges by investing over $1 billion in new manufacturing resources to ensure that we have the long-term supply capabilities to meet public health needs around the world. Specifically, we have modernized some of our processes and equipment at our facility in West Point, Pennsylvania, we are expanding our vaccine manufacturing facilities in Virginia and France, and we are building two new facilities, in North Carolina and Ireland. Our goal is to have additional manufacturing capacity and to create redundancy in our supply chain for certain products, so that we will not experience supply disruptions when temporary issues arise in the manufacture of our vaccines.
The company has, in the past, experienced difficulties manufacturing certain of its animal health products and is currently experiencing difficulty manufacturing certain women’s health products.
In resolving these problems, our goal is to ensure consistent manufacturing and quality standards at these facilities, to drive sustainable compliance excellence and long-term performance at the sites, and to minimize manufacturing issues in the future.
We continue to maintain strict product quality standards and multiple supply chain safeguards to ensure the safety and supply of our products, whether our medicines and vaccines are manufactured internally or externally.
Merck remains committed to the development and commercialization of vaccines and to reestablishing ourselves as a reliable global supplier of quality vaccines and medicines.